STATE OF WISCONSIN INVESTMENT BOARD - DECIPHERA PHARMACEUTICALS IN ownership

DECIPHERA PHARMACEUTICALS IN's ticker is DCPH and the CUSIP is 24344T101. A total of 146 filers reported holding DECIPHERA PHARMACEUTICALS IN in Q1 2023. The put-call ratio across all filers is 0.80 and the average weighting 0.2%.

Quarter-by-quarter ownership
STATE OF WISCONSIN INVESTMENT BOARD ownership history of DECIPHERA PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2023$606,642
-5.2%
47,692
+4.9%
0.00%0.0%
Q2 2023$640,020
-24.1%
45,456
-16.7%
0.00%
-33.3%
Q1 2023$843,045
+32.2%
54,566
+40.3%
0.00%
+50.0%
Q4 2022$637,604
-16.5%
38,902
-5.8%
0.00%0.0%
Q3 2022$764,000
+37.2%
41,289
-2.6%
0.00%
+100.0%
Q2 2022$557,000
-47.1%
42,373
-62.7%
0.00%
-50.0%
Q1 2022$1,053,000
+107.7%
113,600
+118.9%
0.00%
+100.0%
Q4 2021$507,000
-71.3%
51,9000.0%0.00%
-75.0%
Q3 2021$1,764,000
-7.2%
51,9000.0%0.00%0.0%
Q2 2021$1,900,000
-18.3%
51,9000.0%0.00%
-20.0%
Q1 2021$2,327,000
-23.7%
51,900
-2.8%
0.01%
-28.6%
Q4 2020$3,048,000
-10.6%
53,400
-19.7%
0.01%
-22.2%
Q3 2020$3,411,000
-7.0%
66,500
+8.3%
0.01%
-10.0%
Q2 2020$3,667,000
+192.0%
61,400
+101.3%
0.01%
+150.0%
Q1 2020$1,256,000
-8.7%
30,500
+38.0%
0.00%
+33.3%
Q4 2019$1,375,000
+83.3%
22,1000.0%0.00%
+50.0%
Q3 2019$750,000
+176.8%
22,100
+84.2%
0.00%
+100.0%
Q2 2019$271,000
-0.4%
12,000
+2.6%
0.00%0.0%
Q1 2019$272,000
-11.1%
11,700
+48.1%
0.00%0.0%
Q3 2018$306,0007,9000.00%
Other shareholders
DECIPHERA PHARMACEUTICALS IN shareholders Q1 2023
NameSharesValueWeighting ↓
New Leaf Venture Partners, L.L.C. 1,209,571$69,030,00015.95%
SV Health Investors, LLC 449,951$25,679,00012.37%
Sunesis Advisors, LLC 96,299$5,496,0004.45%
Redmile Group, LLC 4,437,968$253,275,0003.07%
Consonance Capital Management LP 484,671$27,660,0002.58%
SECTORAL ASSET MANAGEMENT INC 488,842$27,898,0001.97%
Opaleye Management Inc. 222,000$12,670,0001.66%
Eversept Partners, LP 246,240$14,052,9171.65%
SILVERARC CAPITAL MANAGEMENT, LLC 38,620$2,204,0001.28%
Avoro Capital Advisors LLC 1,300,000$74,191,0001.28%
View complete list of DECIPHERA PHARMACEUTICALS IN shareholders